search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
SURGICAL S I T E INF ECTION


glycaemic control measures. Post-operatively, a restrictive transfusion protocol with single unit transfusions and oozing wound protocols were also introduced through the use of an advanced post-operative wound care dressing. Following the introduction of these and other measures, Ashford and St Peter’s saw significant improvements in outcomes, with mortality rates dropping by 4% and early infection rates reducing to 0.24%. Mean length of stay also fell from 15.7 to 13.8 days, with the project potentially saving £2 million for the hospital.16 Time to Act also highlights best practice case studies demonstrating the impact of collaboration that has taken place at the national level between hospital Trusts. The Quality Improvement for Surgical Teams Programme (QIST) Infection Collaborative brings together 30 hospital Trusts from across England to support SSI reduction. Led by Northumbria Healthcare NHS Foundation Trust and working in partnership with the British Orthopaedic Association, Trusts across the country have been brought together to drive forward improvements in patient care and reduce SSI prevalence. The Collaborative has introduced two complementary care-bundles for mild anaemia and methicillin-susceptible Staphylococcus aureus (MSSA) into routine clinical practice. To support the reduction of MSSA, the Collaborative is scaling up and evaluating the introduction of pre-operative screening, in addition to body washing and nasal gel treatments for patients carrying MSSA. Overall, the Collaborative expects to support savings of up to £6.3 million.17


By working together


in a coordinated and supportive manner and sharing knowledge across trusts, hospitals can develop common solutions and support the implementation across the surgical pathway. These, and the other case studies


included in Time to Act, clearly demonstrate the vital importance of raising the profile of infection control within hospitals and adopting best practice measures across the patient’s surgical journey. In developing the Time to Act report, it became clear that the spirit of collaboration demonstrated, both in hospitals and cross Trust collaborations, needs to be reflected across the health system if we are to fully meet the challenge of SSIs.


How we can all play our part in reducing SSIs The report makes a number of recommendations to stakeholders at every level, from patients to policymakers, from the higher tiers of hospital management to surgical teams themselves. What is clear at the policymaker level is that we do not yet have a true picture of SSI prevalence


JANUARY 2021


in the UK, and, without this, we will never fully understand the scale of the problem with which we are dealing. Time to Act calls for policymakers to both introduce mandatory reporting of SSIs across all surgical specialties


across all four nations of the UK, and clear, deliverable targets to reduce SSIs across all surgical specialties to be set within the lifetime of the five-year, and subsequent 20-year AMR plans.


VIO®


3 plug and operate


Electrosurgery


Handling of the VIO 3 with stepGUIDE, the new modes, and the highest level of flexibility in the selection of instruments, all make for maximum ease of use.


with maximum convenience


Then there are the other advantages: ☑ Reliably reproducible tissue effects thanks to state-of-the-art processor technology ☑ Selection of up to 6 different settings for your procedure from the operating field ☑ Use of up to 6 instruments ☑ Large touchscreen display


Erbe Medical UK Ltd Leeds United Kingdom +44 113 253 0333 erbe-uk.com


AZ_Erbe_VIO_3_210x297_0217.indd 1


03.07.2017 13:18:24 WWW.CLINICALSERVICESJOURNAL.COM l


61





©gpointstudio - stock.adobe.com © Erbe Elektromedizin GmbH 2017 2017-02 D119931 non-US only


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80